Loading...
XASEASXC
Market cap94mUSD
Aug 21, Last price  
0.35USD
Name

Asensus Surgical Inc

Chart & Performance

D1W1MN
XASE:ASXC chart
P/E
—
P/S
11.07
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
73.38%
Rev. gr., 5y
-18.67%
Revenues
9m
+21.02%
000-135,00000-29035,0001,431,000401,00001,519,0007,111,00024,102,0008,531,0003,175,0008,232,0007,087,0008,577,000
Net income
-78m
L+3.80%
-444,000-228,000-204,000-3,041,000-5,185,000-2,366,000-5,303,000-5,758,000-6,724,000-28,358,000-37,652,000-46,948,000-119,980,000-144,796,000-61,777,000-154,201,000-59,312,000-62,462,000-75,561,000-78,433,000
CFO
-64m
L+7.96%
-452,000-219,000-27,000-2,946,000-4,031,000-2,590,000-4,533,000-4,867,000-6,939,000-21,236,000-33,228,000-38,509,000-52,386,000-39,795,000-48,493,000-73,484,000-46,675,000-40,659,000-58,937,000-63,627,000
Earnings
Mar 19, 2025

Profile

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
URL
https://asensus.com/
IPO date
Aug 06, 1991
Employees
183
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,577
21.02%
7,087
-13.91%
8,232
159.28%
Cost of revenue
86,707
74,742
63,162
Unusual Expense (Income)
NOPBT
(78,130)
(67,655)
(54,930)
NOPBT Margin
Operating Taxes
314
318
225
Tax Rate
NOPAT
(78,444)
(67,973)
(55,155)
Net income
(78,433)
3.80%
(75,561)
20.97%
(62,462)
5.31%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,118
(332)
130,866
BB yield
-12.71%
0.40%
-51.95%
Debt
Debt current
2,072
800
683
Long-term debt
9,292
10,276
10,695
Deferred revenue
290
(1,214)
(3,292)
Other long-term liabilities
8,108
1,256
2,371
Net debt
(11,345)
(63,313)
(124,448)
Cash flow
Cash from operating activities
(63,627)
(58,937)
(40,659)
CAPEX
(561)
(1,279)
(1,368)
Cash from investing activities
64,506
47,537
(119,668)
Cash from financing activities
9,626
(332)
161,705
FCF
(83,586)
(66,813)
(55,021)
Balance
Cash
21,067
70,524
98,391
Long term investments
1,642
3,865
37,435
Excess cash
22,280
74,035
135,414
Stockholders' equity
(939,715)
(863,086)
(785,403)
Invested Capital
988,245
967,472
958,925
ROIC
ROCE
EV
Common stock shares outstanding
249,685
236,492
226,960
Price
0.32
-8.12%
0.35
-68.73%
1.11
77.60%
Market cap
79,625
-3.00%
82,086
-67.42%
251,926
469.25%
EV
68,280
18,773
127,478
EBITDA
(74,401)
(56,579)
(40,819)
EV/EBITDA
Interest
410
370
Interest/NOPBT